CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents
Authors
Keywords
-
Journal
Nature Reviews Urology
Volume 11, Issue 1, Pages 32-42
Publisher
Springer Nature
Online
2013-11-26
DOI
10.1038/nrurol.2013.274
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative Evaluation of Radiation Treatments for Clinically Localized Prostate Cancer: An Updated Systematic Review
- (2013) Raveendhara R. Bannuru et al. ANNALS OF INTERNAL MEDICINE
- Drug discovery for breast cancer and co-instantaneous cardiovascular disease: what is the future?
- (2013) Lina Yin et al. Future Medicinal Chemistry
- Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
- (2013) Lina Yin et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cushing’s Syndrome: Development of Highly Potent and Selective CYP11B1 Inhibitors of the (Pyridylmethyl)pyridine Type
- (2013) Juliette Emmerich et al. JOURNAL OF MEDICINAL CHEMISTRY
- Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases
- (2013) Mariano A. E. Pinto-Bazurco Mendieta et al. JOURNAL OF MEDICINAL CHEMISTRY
- Modulation of Cytochromes P450 with Xanthone-Based Molecules: From Aromatase to Aldosterone Synthase and Steroid 11β-Hydroxylase Inhibition
- (2013) Silvia Gobbi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tetrahydropyrroloquinolinone Type Dual Inhibitors of Aromatase/Aldosterone Synthase as a Novel Strategy for Breast Cancer Patients with Elevated Cardiovascular Risks
- (2013) Lina Yin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
- (2012) C. N. Sternberg et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer treatment and survivorship statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Abiraterone Inhibits 3 -Hydroxysteroid Dehydrogenase: A Rationale for Increasing Drug Exposure in Castration-Resistant Prostate Cancer
- (2012) R. Li et al. CLINICAL CANCER RESEARCH
- Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
- (2012) Suzanne George et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel Imidazol-1-ylmethyl Substituted 1,2,5,6-Tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as Potent and Selective CYP11B1 Inhibitors for the Treatment of Cushing’s Syndrome
- (2012) Lina Yin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective Dual Inhibitors of CYP19 and CYP11B2: Targeting Cardiovascular Diseases Hiding in the Shadow of Breast Cancer
- (2012) Qingzhong Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
- (2012) Masuo Yamaoka et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
- (2012) Christopher J Logothetis et al. LANCET ONCOLOGY
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
- (2012) Natasha M. DeVore et al. NATURE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- 3-Pyridyl Substituted Aliphatic Cycles as CYP11B2 Inhibitors: Aromaticity Abolishment of the Core Significantly Increased Selectivity over CYP1A2
- (2012) Lina Yin et al. PLoS One
- A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects
- (2012) Milin Acharya et al. XENOBIOTICA
- Synthesis and biological evaluation of imidazolylmethylacridones as cytochrome P-450 enzymes inhibitors
- (2012) Ashraf H. Abadi et al. MedChemComm
- Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
- (2011) Tomohiro Kaku et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
- (2011) C. Cai et al. CANCER RESEARCH
- Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone: Figure 1.
- (2011) James L. Mohler et al. CLINICAL CANCER RESEARCH
- Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
- (2011) Elahe A. Mostaghel et al. CLINICAL CANCER RESEARCH
- Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response
- (2011) C. J. Ryan et al. CLINICAL CANCER RESEARCH
- Direct Regulation of Androgen Receptor Activity by Potent CYP17 Inhibitors in Prostate Cancer Cells
- (2011) Harris S. Soifer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Future of Drug Development in Urothelial Cancer
- (2011) Robert Dreicer JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Patients With Advanced Neurofibromatosis Type 2 With Novel Molecularly Targeted Therapies: From Bench to Bedside
- (2011) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone
- (2011) Eleni Efstathiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
- (2011) K.-H. Chang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): Head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model
- (2011) Robert D. Bruno et al. STEROIDS
- The Role of Fluorine Substitution in Biphenyl Methylene Imidazole-Type CYP17 Inhibitors for the Treatment of Prostate Carcinoma
- (2010) Qingzhong Hu et al. ChemMedChem
- Longitudinal Study of Depressive Symptoms in Patients With Metastatic Gastrointestinal and Lung Cancer
- (2010) Christopher Lo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
- (2010) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
- (2010) Alison H.M. Reid et al. JOURNAL OF CLINICAL ONCOLOGY
- Isopropylidene Substitution Increases Activity and Selectivity of Biphenylmethylene 4-Pyridine Type CYP17 Inhibitors
- (2010) Qingzhong Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Replacement of Imidazolyl by Pyridyl in Biphenylmethylenes Results in Selective CYP17 and Dual CYP17/CYP11B1 Inhibitors for the Treatment of Prostate Cancer
- (2010) Qingzhong Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Steroidogenic cytochrome P450 (CYP) enzymes as drug targets: Combining substructures of known CYP inhibitors leads to compounds with different inhibitory profile
- (2009) Ulrike E. Hille et al. COMPTES RENDUS CHIMIE
- Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit
- (2009) Pim J. van Leeuwen et al. EUROPEAN JOURNAL OF CANCER
- Novel CYP17 inhibitors: Synthesis, biological evaluation, structure–activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls
- (2009) Ulrike E. Hille et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Molecular mechanisms of castration-resistant prostate cancer progression
- (2009) Smitha S Dutt et al. Future Oncology
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005
- (2009) H. G. Welch et al. JNCI-Journal of the National Cancer Institute
- CYP17 Inhibitors. Annulations of Additional Rings in Methylene Imidazole Substituted Biphenyls: Synthesis, Biological Evaluation and Molecular Modelling
- (2008) Mariano A. E. Pinto-Bazurco Mendieta et al. ARCHIV DER PHARMAZIE
- Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17)—Part II: Core rigidification and influence of substituents at the methylene bridge
- (2008) Qingzhong Hu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Androgen receptor and growth factor signaling cross-talk in prostate cancer cells
- (2008) M.-L. Zhu et al. ENDOCRINE-RELATED CANCER
- The role of testosterone in the pathogenesis of prostate cancer
- (2008) Takashi Imamoto et al. INTERNATIONAL JOURNAL OF UROLOGY
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31
- (2008) Jason A. Efstathiou et al. JOURNAL OF CLINICAL ONCOLOGY
- 17 -Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response
- (2008) R. D. Bruno et al. MOLECULAR CANCER THERAPEUTICS
- Androgen receptor inactivation contributes to antitumor efficacy of 17 -hydroxylase/17,20-lyase inhibitor 3 -hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
- (2008) T. Vasaitis et al. MOLECULAR CANCER THERAPEUTICS
- Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure
- (2007) Carsten Jagusch et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Regulation of the adrenal androgen biosynthesis
- (2007) William E. Rainey et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started